Shares of Inhibrx, Inc. (INBX) are rising more than 7% Tuesday morning after the company said Aventis Inc., a unit of Sanofi, has agreed to acquire all the assets and liabilities associated with INBRX-101, an augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency (AATD), for about $2.2 billion.
Prior to the closing of the transaction, Inhibrx will form a new publicly traded company, Inhibrx Biosciences, Inc. with its other assets and liabilities including INBRX-105, INBRX-106, INBRX-109.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com